Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M37,672Revenue (TTM) $M6,638Net Margin (%)19.9Altman Z-Score2.5
Enterprise Value $M43,897EPS (TTM) $6.7Operating Margin %22.7Piotroski F-Score5
P/E(ttm)32.7Beneish M-Score-2.6Pre-tax Margin (%)21.4Higher ROA y-yN
Price/Book4.010-y EBITDA Growth Rate %--Quick Ratio0.4Cash flow > EarningsY
Price/Sales6.55-y EBITDA Growth Rate %21.9Current Ratio0.6Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %-42.3ROA % (ttm)7.1Higher Current Ratio y-yY
Dividend Yield %0.4PEG1.5ROE % (ttm)13.8Less Shares Outstanding y-yN
Payout Ratio %12.0Shares Outstanding M197ROIC % (ttm)11.2Gross Margin Increase y-yY

Gurus Latest Trades with SHPG

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
SHPGJohn Paulson 2016-03-31 Add0.29%$150.4 - $205
($168.09)
$ 190.8614%Add 3.31%7,071,050
SHPGFirst Eagle Investment 2016-03-31 Add0.02%$150.4 - $205
($168.09)
$ 190.8614%Add 873.75%47,032
SHPGDavid Dreman 2016-03-31 Buy $150.4 - $205
($168.09)
$ 190.8614%New holding154
SHPGKen Fisher 2016-03-31 Add$150.4 - $205
($168.09)
$ 190.8614%Add 16.80%39,657
SHPGLeon Cooperman 2015-12-31 Sold Out -0.19%$188.55 - $231.08
($207.82)
$ 190.86-8%Sold Out0
SHPGJohn Paulson 2015-12-31 Add0.05%$188.55 - $231.08
($207.82)
$ 190.86-8%Add 0.58%6,844,800
SHPGKen Fisher 2015-12-31 Add$188.55 - $231.08
($207.88)
$ 190.86-8%Add 9.30%33,954
SHPGLeon Cooperman 2015-09-30 Reduce-1.74%$197.88 - $268.08
($237.86)
$ 190.86-20%Reduce -90.86%45,367
SHPGJohn Paulson 2015-09-30 Reduce-0.33%$197.88 - $268.08
($237.86)
$ 190.86-20%Reduce -4.09%6,805,200
SHPGKen Fisher 2015-09-30 Add$197.88 - $268.08
($237.86)
$ 190.86-20%Add 54.08%31,064
SHPGJohn Paulson 2015-06-30 Reduce-1.55%$226.9 - $260.15
($247.87)
$ 190.86-23%Reduce -14.81%7,095,100
SHPGFirst Eagle Investment 2015-06-30 Reduce-0.17%$226.9 - $260.15
($247.87)
$ 190.86-23%Reduce -98.36%4,830
SHPGLeon Cooperman 2015-06-30 Reduce-0.02%$226.9 - $260.15
($247.87)
$ 190.86-23%Reduce -0.80%496,192
SHPGKen Fisher 2015-06-30 Add$226.9 - $260.15
($247.87)
$ 190.86-23%Add 36.31%20,161
SHPGFirst Eagle Investment 2015-03-31 Add0.12%$205.66 - $253.64
($229.81)
$ 190.86-17%Add 254.93%294,539
SHPGLeon Cooperman 2015-03-31 Add0.1%$205.66 - $253.64
($229.81)
$ 190.86-17%Add 5.70%500,192
SHPGMario Gabelli 2015-03-31 Sold Out -0.018%$205.66 - $253.64
($229.81)
$ 190.86-17%Sold Out0
SHPGKen Fisher 2015-03-31 Add$205.66 - $253.64
($229.81)
$ 190.86-17%Add 1.35%14,791
SHPGLeon Cooperman 2014-12-31 Buy 1.7%$170.49 - $262.71
($211.39)
$ 190.86-10%New holding473,237
SHPGJohn Paulson 2014-12-31 Reduce-0.77%$170.49 - $262.71
($211.41)
$ 190.86-10%Reduce -7.93%8,328,304
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

SHPG is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


SHPG: Insider Buys/Sells

Click Here for All Insider Trades.

No Insider Trades Found!

Quarterly/Annual Reports about SHPG:

News about SHPG:

Articles On GuruFocus.com
Tweedy Browne Global Value Fund Makes Trades Around the World Jul 12 2016 
Tweedy Browne Fund 4th Quarter Commentary Jan 27 2016 
John Paulson Sells Stake in Broadcom, Cuts Cablevision Holding Nov 18 2015 
Undervalued Baxalta Shares Target of Acquisition by Shire Plc Aug 05 2015 
Manning & Napier's Top 5 New Stock Buys of Q2 Jul 09 2015 
Manning & Napier Invests in Stake in Baidu Jul 08 2015 
Invesco European Growth Fund Parts With Two Stakes Jul 01 2015 
Andreas Halvorsen Increases Stake in Esperion Therapeutics Jun 29 2015 
Smart Guru John Paulson Bullish on Actavis Jun 18 2015 
8 Top Healthcare Stocks to Watch May 13 2015 

More From Other Websites
What to Expect from Shire’s Genetic Disease Franchise Jul 28 2016
How Will Major Drugs in GI Franchise Perform in 2Q16? Jul 27 2016
How Will Shire’s ADHD Franchise Perform in 2Q16? Jul 27 2016
How Much Revenue Growth Will Shire Record in 2Q16? Jul 26 2016
What Do Analysts Recommend for Shire? Jul 26 2016
Top Analyst Thinks Big Pharmaceutical Stocks Will Outperform the Rest of 2016 Jul 26 2016
ADYNOVATE PHASE 3 EFFICACY AND SAFETY ... Jul 26 2016
7:03 am Shire plc to present additional data of ADYNOVATE Phase 3 efficacy and safety at the... Jul 26 2016
ADYNOVATE Phase 3 Efficacy and Safety Data in Children to be Showcased During International Congress... Jul 26 2016
Specialty Pharma: Earnings Better Be Good…or Else Jul 25 2016
ONIVYDE® Receives Positive ... Jul 25 2016
Merrimack Announces ONIVYDE® Regimen Receives Positive CHMP Opinion in European Union Jul 25 2016
ONIVYDE® Receives Positive CHMP Opinion for Treatment of Patients with Metastatic Adenocarcinoma of... Jul 25 2016
How Analysts Think Investors Should Play Vertex Pharmaceuticals Jul 21 2016
Valeant & Endo: Imagining a World With No Drug Pricing Controversies Jul 21 2016
Shire Launches Pediatric Indication for Immunodeficiency Treatment HyQvia in Europe Jul 21 2016
SHIRE PLC Files SEC form 8-K, Financial Statements and Exhibits Jul 20 2016
Shire Reinforces Commitment in Hematology with Robust Data Presented at International Congress of... Jul 19 2016
Shire Could Divest ADHD Treatment, Other Assets, for More Upside Post-Baxalta Jul 14 2016
Coverage Initiated on Select Healthcare Stocks Jul 14 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)